AI-generated summary
The authors compared low-fluence 1064-nm Q-switched Nd:YAG laser treatment alone (with placebo peel) against the same laser combined with Jessner's solution peeling in 52 melasma patients, using a double-blind design. At 8 weeks, the combined group showed a larger reduction in MASI scores, but at 20 weeks the groups did not differ significantly. No serious adverse effects were reported with the added peel.
- Participants
- 52
- Who or what was studied
- Patients with melasma
- Wavelengths
- 1064 nm
- Limits stated in the abstract
- The abstract reports only a short-term early advantage that disappeared by 20 weeks, and it does not describe the sample size calculation or the number of patients per group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on tandfonline.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Fluence, Laser, Placebo-controlled. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.